GENETICS OF MAJOR DEPRESSIVE DISORDER

Pomohaibo V. M., Berezan O. I., Petrushov A. V.

LITERATURE REVIEWS

Scentific article

Major depressive disorder (MDD) is prevalent psychiatric disease with hereditary liability. It develops as a interaction result of genetic components and certain environmental factors. According to the results of the WHO investigation, the average global prevalence of major depressive disorder is 5%. There is a regional variation of this index, so that low prevalence is found in East and South-East Asia and sub-Saharan Africa, whereas higher prevalence is found in North and South America, North Africa and some European countries. Women have 1.5- 2.0 times risk of developing depression compared with men. Depression is more common among young people than among old people. The results of population study show that in family generations there is not clear pattern of inheritance of major depressive disorder, and it may appear in the family even when ancestral patients in the pedigree are absent. The depression inheritance is negligible and is about 40%. Thus, in the disorder development certain environmental factors are predominant: negative experiences in childhood, adverse life events, etc. The risk of developing depression may be increased in a presence of some nonmental diseases – diabetes, obesity, and cardiovascular disease. The liability to depression is determined by a complex set of genes, each of which separately has a little effect. In addition, the set and the intensity of symptom expressions of different patients with major depression are varied extremely, making it difficult to determine the clear boundary between disorder and health. To study moleculargenetic mechanisms of MDD four methods are used: genome-wide linkage analysis, selection of candidate genes, genome-wide association studies, and resequencing. These methods allowed to identify 3 genomic regions (3p25- p26, 12q22-q24, 15q25-q26) and 10 genes (APOE, C5orf20, DRD4, GNB3, MTHFR, NPV, SLC6A2, SLC6A3, SLC6A4, TNF) that were associated with depression. Among the candidate genes, three genes associated with stress responses to be most attracted: DRD4, NPY, and SLC6A2. The DRD4 gene (11p15.5) encodes one in protein subunits of the dopamine receptor. This receptor participates in regulation of emotion and complex behavior. The NPY gene (7p15.3) encodes a neuropeptide Y, which is an active neurotransmitter in the central nervous system, and has an effect on cortical excitability, stress response, dietary, daily rhythms, and cardiovascular function. The SLC6A2 gene (16q12.2) encodes a noradrenaline neurotransmitter, which provides a reverse movement of this hormone through the presynaptic membrane after the stressful period passed. The method of genome-wide association allows to detect such damages of genome-wide DNA as these: single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), small insertions/deletions (In/Del) and copy number variations (CNVs), part of which may be associated with depression. There were identified 4 SNPs: in the genes SLC6A15 and GPHN, in the region 16p11.2 and in the 5q21 noncoding region, which resides with the closest gene NUDT12, and 5 CNVs in the regions 7p21.3, 15q26.3, 15q35.1, 16p11.2 and 18p11.32. Due to resequencing it was determined the association of MDD with a number of SNPs – 6 in the gene BDNF, 2 in the gene AANAT and 1 in the gene LIPG. The BDNF gene (11p14.1) is related to the development of the central nervous system. It encodes the neurotrophic brain factor – a protein that stimulates and supports neurons development. The product of the AANAT gene (17q25.1) is involved in sleep regulation, as a key enzyme of the melatonin pathway. It is necessary to admit that we known about the genetic bases of liability to MDD still not enough. The study of these bases is restrained by lack of sufficient knowledge of the main links of complex network of neurophysiologic processes and biological pathway of MDD development.

depressive disorder, hereditary liability, linkage, candidate genes, genome-wide association, resequencing, single nucleotide polymorphisms, single nucleotide variants, small insertions/deletions, copy number variations.

1. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013. р. 160-8.
2. Pomohaibo VM, Berezan OI, Petrushov AV. Henetyka bipoliarnoho rozladu. Visnyk problem biolohii i medytsyny. 2018;4,2(147):62-5. [in Ukrainian].
3. Pomohaibo VM, Berezan OI, Petrushov AV. Henetyka rozladiv autystychnoho spektru. Svit medytsyny ta biolohii. 2017;1(59):208-12. [in Ukrainian].
4. Pomohaibo VM, Berezan OI, Petrushov AV. Henetyka syndromu defitsytu uvahy z hiperaktyvnistiu. Psykholohiia i osobystist. 2018;1(13):171- 82. [in Ukrainian].
5. Pomohaibo VM, Berezan OI, Petrushov AV. Shyzofreniia: poshuky henetychnykh faktoriv ryzyku. Psykholohiia i osobystist. 2019;1(15):241-52. [in Ukrainian].
6.  Markkula N. Prevalence, predictors and prognosis of depressive disorders in the general population [dissertation]. Helsinki: University of Helsinki; 2016. 128 p.
7. Talati A, Weissman MM, Hamilton SP. Using the high-risk family design to identify biomarkers for major depression. Phil. Trans. R. Soc. B. 2013 Jan 29;368(1615):1-10.
8. Fried EI. Problematic assumptions have slowed down depression research: why symptoms, not syndromes are the way forward. Front. Psychol. 2015 Mar 23;6(309):1-11.
9.  Levinson DF. Genetics of major depression. In: Handbook of depression. 2nd ed. Eds. Gotlib IH, Hammen CL. N.Y.: The Guilford Press; 2009. р. 165-86.
10. Pergadia ML, Glowinski AL, Wray NR, Agrawal A, Saccone SF, Loukola A, et al. A 3p26-3p25 genetic linkage finding for DSM-IV major depression in heavy smoking families. Am. J. Psychiatry. 2011 Aug 1;168(8):848-52.
11.  Abkevich V, Camp EJ, Hensel CH, Neff ChD, Russell DL, Hughes DC, et al. Predisposition locus for major depression at chromosome 12q22– 12q23.2. Am. J. Hum. Genet. 2003 Nov 5;73(6):1271-81.
12. McGuffin P, Knight J, Breen G. Whole genome linkage scan of recurrent depressive disorder from the depression network study. Hum. Mol. Genet. 2005 Oct 3;14(22):3337-45.
13. Holmans P, Weissman MM, Zubenko GS, Scheftner WA, Crowe RR, DePaulo JR, et al. Genetics of recurrent early-onset major depression (GenRED): final genome scan report. Am. J. Psychiatry. 2007 Feb 1;164(2):248-58.
14. Shyn SI, Hamilton SP. The genetics of major depression: moving beyond the monoamine hypothesis. Psychiatr. Clin. North Am. 2010 Mar;33(1):125-40.
15.  López-León S, Janssens AC, González-Zuloeta Ladd M, Del-Favero J, Claes SJ, Oostra BA, et al. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry. 2008 Oct 16;13(8):772-85.
16.  Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry. 2010 Mar 30;16(5):516-32.
17. Human Gene Database [Internet]. 2017 [updated 2017 June 15] Available from: http://www.genecards.org; http://www.malacards.org
18.  Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit LH, Zandbelt T, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol. Psych. 2008 Dec 9;14(4):359-75.
19. Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, et al. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron. 2011 Apr 28;70(2):252-65.
20.  Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. Psychiatry. 2012 Apr 3;18(4):497-511.
21. Hek K, Demirkan A, Lahti J, Terracciano A, Teumer A, Cornelis MC, et al. A genome-wide association study of depressive symptoms. Biol. Psychiatry. 2013 Sep 12;73:667-78.
22. Glessner JT, Wang K, Sleiman PM, Zhang H, Kim CE, Flory JH, et al. Duplication of the SLIT3 locus on 5q35.1 predisposes to major depressive disorder. PLoS One. 2010 Dec 1;5(12):е15463.
23. Degenhardt F, Priebe L, Herms S, Mattheisen M, Mühleisen TW, Meier S, et al. Association between copy number variants in 16p11.2 and major depressive disorder in a German case-control sample. Am. J. Med. Genet. Part B: Neuropsychiatric Genetics. 2012 Jan 24;159B(3):263- 73.
24. Licinio J, Dong Ch, Wong M-L. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry. 2009 May;66(5):488-97.
25. Soria V, Martínez-Amorós È, Escaramís G, Valero J, Crespo JM, Gutiérrez-Zotes A, et al. Resequencing and association analysis of arylalkylamine N-acetyltransferase (AANAT) gene and its contribution to major depression susceptibility. J. Pineal Res. 2010 Feb 25;49(1):35-44.
26. Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet. Genomics. 2013 Mar;23(3):156-66.
27.  Verbeek EC, Bevova MR, Bochdanovits Z, Rizzu P, Bakker IMC, Uithuisje Е, et al. Resequencing three candidate genes for major depressive disorder in a Dutch cohort. PLoS ONE. 2013 Nov 21;8(11):e79921.
28.  Amin N, Jovanova O, Adams HH, Dehghan A, Kavousi M, Vernooij MW, et al. Exome-sequencing in a large population-based study reveals a rare Asn396Ser variant in the LIPG gene associated with depressive symptoms. Mol. Psychiatry. 2017 Apr;22(4):537-43.

«Bulletin of problems biology and medicine» Issue 1 Part 2 (149), 2019 year, 40-45 pages, index UDK 616.89

10.29254/2077-4214-2019-1-2-149-40-45